Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma - PDF (俄文)
版权所有 © Consilium Medicum, 2019
![Creative Commons License](http://licensebuttons.net/l/by-nc-sa/4.0/88x31.png)
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。